BeOne Medicines Ltd.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $286.9M | $-644.8M | $-881.7M | $-2.00B | $-1.46B | $-1.62B | $-948.6M | $-673.8M |
| Depreciation & Amortization | $141.7M | $171.8M | $87.7M | $66.3M | $46.5M | $31.8M | $18.6M | $10.4M |
| Depreciation | $131.6M | $166.9M | $80.4M | $62.3M | $44.7M | $30.9M | $17.3M | $9.0M |
| Amortization | $10.1M | $4.8M | $7.2M | $4.0M | $1.7M | $846.0K | $1.3M | $894.0K |
| Stock-Based Compensation | $510.9M | $441.6M | $367.6M | $303.2M | $240.7M | $183.5M | $134.2M | $87.1M |
| Net Cash from Operating Activities | $1.13B | $-140.6M | $-1.16B | $-1.50B | $-1.30B | $-1.28B | $-750.3M | $-547.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $185.8M | $492.7M | $561.9M | $325.4M | $262.9M | $117.5M | $89.6M | $70.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-276.2M | $-548.4M | $60.0M | $1.08B | $640.7M | $-3.17B | $554.2M | $-637.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.06B | $193.4M | $416.5M | $-19.0M | $3.64B | $5.20B | $85.7M | $1.69B |
| Net Change in Cash | $1.97B | $-547.2M | $-689.1M | $-507.9M | $2.99B | $769.2M | $-119.9M | $501.1M |
| Free Cash Flow | $941.7M | $-633.3M | $-1.72B | $-1.82B | $-1.56B | $-1.40B | $-839.9M | $-618.0M |